CompletedPhase 2NCT01980628
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Studying Nodal marginal zone B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pharmacyclics LLC.
- Principal Investigator
- Isaiah Dimery, MDPharmacyclics LLC.
- Intervention
- ibrutinib(drug)
- Enrollment
- 63 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2017
Study locations (25)
- Site Reference ID/Investigator# 837, Tucson, Arizona, United States
- Site Reference ID/Investigator# 047, Duarte, California, United States
- Site Reference ID/Investigator# 377, Santa Monica, California, United States
- Site Reference ID/Investigator# 763, West Palm Beach, Florida, United States
- Site Reference ID/Investigator# 033, Atlanta, Georgia, United States
- Site Reference ID/Investigator# 370, Chicago, Illinois, United States
- Site Reference ID/Investigator# 195, Detroit, Michigan, United States
- Site Reference ID/Investigator# 350, New Hyde Park, New York, United States
- Site Reference ID/Investigator# 745, New York, New York, United States
- Site Reference ID/Investigator # 200, New York, New York, United States
- Site Reference ID/Investigator # 407, New York, New York, United States
- Site Reference ID/Investigator# 220, Hershey, Pennsylvania, United States
- Site Reference ID/Investigator# 348, Seattle, Washington, United States
- Site Reference ID/Investigator# 560, Ghent, Oost-vlaanderen, Belgium
- Site Reference ID/Investigator# 142, Pierre-Bénite, Auvergne-Rhône-Alpes, France
- +10 more locations on ClinicalTrials.gov
Collaborators
Janssen Research & Development, LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01980628 on ClinicalTrials.gov